1-9 of 9
Ayad Al-Katib, MD
Close
Sort by
Journal Articles

A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma

Ayad Al-Katib, MD, Timothy M. Kuzel, MD, Ralph Parchment, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4041.
https://doi.org/10.1182/blood-2019-127278
Published: 2019
Journal Articles

Isolation and Characterization of a CD34 + Sub-Clone in B-Cell Lymphoma

Ayad Al-Katib, MD, Ebrahim Abdul Shukkur, PhD, Ali M Gabali, MD PhD, ALI Raufi, MD, Salah Ebrahim, MD, Mustapha Kandouz, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3970.
https://doi.org/10.1182/blood-2019-130738
Published: 2019
Journal Articles

The Utility of End of Treatment PET-CT in Patients with Diffuse Large B-Cell Lymphoma and Documented Complete Remission By Interim PET

Dahlia Sano, MBBCH, Susan Szpunar, Kleanthe Kolizeras, Ayad Al-Katib, MD FACP
Journal: Blood
Blood (2017) 130 (Supplement 1): 4702.
https://doi.org/10.1182/blood.V130.Suppl_1.4702.4702
Published: 2017
Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Wendi Rodrigueza, PhD, Michael Woolliscroft, BA, MBA, Mina Sooch, BS, MBA, Richard A. Messmann, MD MHS, MSc, Ayad Al-Katib, MD FACP
Journal: Blood
Blood (2014) 124 (21): 1716.
https://doi.org/10.1182/blood.V124.21.1716.1716
Published: 2014
Journal Articles

The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Wael A. Harb, MD, Nehal Lakhani, MD, PhD, Ana Logsdon, LPN, Clinical Research Coordinator, Mary Steigelman, RN, Heidi Smith-Green, BSN, RN, Shari Gaylor, RN, Michael Woolliscroft, BA, MBA, Wendi Rodrigueza, Ph.D., Mina Sooch, BS, MBA, Richard A. Messmann, MD, MHS, MSc, Ayad Al-Katib, MD, FACP
Journal: Blood
Blood (2013) 122 (21): 88.
https://doi.org/10.1182/blood.V122.21.88.88
Published: 2013
Journal Articles

Anti CD-20 Radioimmunotherapy (RIT) Can Be Safely and Effectively Delivered in a Community-Based Hospital

Ayad Al-Katib, MD, FACP, Mary Mandziara, NP, Susan Szpunar, PhD, Kleanthe Kolizeras, BS, Mary Steigelman, RN, John Kalabat, MD, Zyad Kafri, MD
Journal: Blood
Blood (2011) 118 (21): 4991.
https://doi.org/10.1182/blood.V118.21.4991.4991
Published: 2011
Journal Articles

Development of a Novel Small Molecule CRM-1 Inhibitor for Non Hodgkin's Lymphoma

Asfar Sohail Azmi, Research Associate, Ayad Al-Katib, MD, FACP, Amro Aboukameel, RA, Michael Kauffman, MD, Ph.D., Dilara McCauley, Research Associate, Ramzi Mohammad, PhD, Sharon Shacham, PhD
Journal: Blood
Blood (2011) 118 (21): 598.
https://doi.org/10.1182/blood.V118.21.598.598
Published: 2011
Journal Articles

The Utility of Bilateral Bone Marrow Biopsy in the Staging of Non-Hodgkin's Lymphoma

Zyad Kafri, MD, Marwan Al-Hajeili, MD, Muhammad I Zulfiqar, MD, FRCP(C), Asif S Shahab, MD, Abdul Mannan, MD, Susan Szpunar, PhD, Michelle Bonnett, MD, Ayad Al-Katib, MD, FACP
Journal: Blood
Blood (2011) 118 (21): 4769.
https://doi.org/10.1182/blood.V118.21.4769.4769
Published: 2011
Journal Articles

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Ayad Al-Katib, MD, David D. Hurd, MD, Robert Raju, MD, Joe Stephenson, MD, Francis Giles, MD, Eric Haltom, Margaret J. Uprichard, PharmD
Journal: Blood
Blood (2004) 104 (11): 1403.
https://doi.org/10.1182/blood.V104.11.1403.1403
Published: 2004